2,847 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Acquired by Teacher Retirement System of Texas

Teacher Retirement System of Texas purchased a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,847 shares of the medical research company's stock, valued at approximately $693,000.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Bio-Rad Laboratories by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 1,919,808 shares of the medical research company's stock valued at $630,676,000 after buying an additional 12,168 shares during the period. Dimensional Fund Advisors LP grew its stake in Bio-Rad Laboratories by 14.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 746,119 shares of the medical research company's stock worth $245,106,000 after buying an additional 91,690 shares during the last quarter. Earnest Partners LLC increased its position in Bio-Rad Laboratories by 2.1% in the fourth quarter. Earnest Partners LLC now owns 618,049 shares of the medical research company's stock worth $203,035,000 after buying an additional 12,500 shares during the period. Ariel Investments LLC lifted its stake in Bio-Rad Laboratories by 48.0% in the fourth quarter. Ariel Investments LLC now owns 560,524 shares of the medical research company's stock valued at $184,138,000 after buying an additional 181,829 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Bio-Rad Laboratories by 705.9% in the 4th quarter. Bank of America Corp DE now owns 427,292 shares of the medical research company's stock worth $140,370,000 after acquiring an additional 374,269 shares during the period. 65.24% of the stock is owned by institutional investors and hedge funds.

Bio-Rad Laboratories Price Performance

Shares of NYSE BIO traded down $3.34 during midday trading on Friday, reaching $246.31. 250,935 shares of the company were exchanged, compared to its average volume of 306,588. Bio-Rad Laboratories, Inc. has a one year low of $211.43 and a one year high of $387.99. The stock has a market cap of $6.70 billion, a P/E ratio of -3.23 and a beta of 0.95. The company has a quick ratio of 4.43, a current ratio of 5.99 and a debt-to-equity ratio of 0.18. The stock's 50-day moving average price is $238.30 and its 200-day moving average price is $266.78.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, topping analysts' consensus estimates of $1.73 by $0.81. Bio-Rad Laboratories had a positive return on equity of 4.32% and a negative net margin of 85.16%. The company had revenue of $585.40 million for the quarter, compared to analyst estimates of $573.01 million. During the same period in the previous year, the firm earned $2.30 earnings per share. The firm's quarterly revenue was down 4.2% on a year-over-year basis. On average, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BIO. Citigroup cut their price target on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a report on Friday, May 2nd. UBS Group reduced their price target on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Wells Fargo & Company cut their target price on Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating on the stock in a report on Monday, June 9th. Royal Bank Of Canada reduced their price objective on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Finally, Wall Street Zen lowered Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, July 13th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $324.25.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.